pTau217 Biomarker Assay

Frontage introduces a new ultrasensitive assay for the quantitative determination of pTau217 in human plasma, serum, and cerebrospinal fluid (CSF), one of the most promising blood-based biomarkers of Alzheimer’s disease.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

This field is for validation purposes and should be left unchanged.

pTau217 Biomarker Assay

Resources to Consider

Biomarkers Assay List – May 2023

Sequencing Assays for Biomarker Discovery and Pharmacodynamics in...

Biomarker and Alzheimer’s disease: role of high sensitivity...

A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a...

Biomarkers in Alzheimer’s Disease

Companion Diagnostic Biomarkers: Importance, Trend, and Forecast

The Importance of Biomarker Discovery and Personalized Medicine

Analyzing Biomarkers in Drug Development

Bioanalytical Biomarkers

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...

Quantitative Assessment of mRNA Drug Biological Activity by...

A GxP-Qualified dPCR-Based RCL Assay to Quantify Replication...